PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

Phase 2 Completed 23 enrolled Shanghai Jiao Tong University School of Medicine

NaSingle-groupOpen-labelPrevention

Summary

All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at Day +15.

Timeline

Start: 2019-01-01
Primary completion: 2021-05-01
Completion: 2021-05-01

Publications

Jiang JL, Gao WH, Wang LN, Wan M, Wang L, Hu J. Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study. Front Med (Lausanne). 2021 Mar 18;8:630160. doi: 10.3389/fmed.2021.630160. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anti-Thymoglobulin	Unknown	2.5 mg/kg	—
Background	Cyclophosphamide	Other / unclassified	50 mg/kg	—
Background	Tacrolimus	Small molecule	—	—

PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

Summary

Timeline

Publications

Drugs

Indications